Keith Dionne's Casma lines up a $50M venture round to continue the preclinical work on a cellular recycling program
Two years after launching out of Third Rock’s incubator, Casma Therapeutics has landed a $50 million Series B for preclinical development of its muscular dystrophy and Autophagy Degrader Platform (ADP) programs.
Casma kicked off in 2018 with a $58.5 million Series A and a staff of experts in autophagy, the cell’s “garbage disposal.” The biotech’s TRPML1 agonist program for muscular dystrophy is expected to hit the clinic in 2022, according to CEO Keith Dionne, and the ADP program is about a year behind that.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.